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To investigate the transforming activity of human papillomavirus (HPV) E6 and E7 genes in vivo, we previously established
transgenic mouse lines containing HPV16E6E7, in which male mice develop a Leydig cell tumors with a very high incidence.
Because HPV-induced carcinogenesis is highly related to p53, we changed the dose of p53 gene in the transgenic lines by
the mice crossing with p53-disrupted mice. The transgenic mice with homozygous wild-type p53 alleles developed only the
testicular tumor, whereas novel T cell lymphomagenesis occurred in the heterozygous p53–disrupted E6E7 (p531/2E6E7)
transgenic mice. In this tumor and even in the normal spleen, the absence of p53 protein was observed, whereas the p53
mRNA was expressed with a normal size, suggesting the degradation of p53 protein in these tissues. These results suggest
that HPV16E6 could stimulate p53 protein degradation in mouse cells and induced the lymphomagenesis in a manner
indistinguishable from p53 deficiency. © 1998 Academic Press
INTRODUCTION
The genomes of certain types of human papillomavi-
rus (HPV), such as HPV types 16 and 18, which are also
called high-risk HPVs, are frequently found in carcinoma
and precancerous lesions of the uterine cervix, suggest-
ing a causal relationship between infection and carcino-
genesis (zur Hausen, 1989). The E6 and E7 genes of
these viruses together can efficiently transform cell lines
of rodent fibroblasts and immortalize primary fibroblasts,
human keratinocytes, and mammary epithelial cells
(Band et al., 1991; Kanda et al., 1988; Munger et al., 1989;
Yutsudo et al., 1988). The transforming activity of E6 is
highly associated with host p53. Biochemical studies
have shown that the E6 oncoprotein of high-risk HPVs
directly binds to p53 tumor suppressor protein and de-
stroys it via stimulation of ubiquitin-dependent proteoly-
sis (Inoue et al., 1992; Scheffner et al., 1990; Vousden,
1994; Werness et al., 1990). Inactivation of p53 is also
indispensable to human cervical cancer development,
where the p53 protein is absent in HPV-positive tumors,
whereas subtle mutations in the p53 allele are frequently
found in HPV-negative tumors (Scheffner et al., 1991). In
this study, we investigated the transforming activity of
HPV16 oncogenes in relation to p53 in a transgenic
mouse system.
We previously established transgenic mouse lines
containing HPV16E6E7 oncogenes, in which male mice
develop Leydig cell tumors with a very high incidence
(Kondoh et al., 1991, 1994, 1995). To confirm the possibil-
ity that the testicular tumorigenesis is related to p53, HPV
transgenic mice were crossed with p53-disrupted mice
(Tsukada et al., 1993). Even when the p53 gene dosage
was reduced to half, there essentially was no change in
the testicular tumorigenesis. Nevertheless, disappear-
ance of the p53 protein was observed in the hematopoi-
etic organs of the same mice, which might have been the
cause of T cell lymphomagenesis, comparable to that in
p53-null mice.
RESULTS
p53 in the testicular tumors
We first examined the expression of p53 in the normal
testis and the testicular tumor by Northern blot and
immunoprecipitation-associated Western blot analyses.
The expression of p53 mRNA and protein was detected
in all tumors analyzed (Fig. 1). To test the possibility that
testicular tumorigenesis was related to p53 status, the
HPV transgenic mice were crossed with p53-disrupted
mice. However, we could obtain no transgenic mice with
p53 disruption (p532/2E6E7), suggesting embryo lethal-
ity. We did not observe any changes in testicular tumor-
igenesis in the heterozygous p53–disrupted E6E7 trans-
genic mice (p531/2E6E7) (data not shown).
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Novel lymphomagenesis in the p531/2E6E7
transgenic mice
Although we observed no change in the testicular
tumorigenesis, all p531/2E6E7 transgenic mice had
lymphoma, which was never found in the original 181
transgenic line (p531/1E6E7). During 3–6 months after
birth, the thymic hypertrophy, splenomegaly, and sys-
temic lymph node enlargement could be seen in all
p531/2E6E7 transgenic mice, and all animals died by 7
months (Fig. 2). These organs were occupied by tumor
cells with the morphology of immature lymphoid cells,
with coarse, large nuclei showing punctuated nucleoli
and narrow cytoplasm. Invasion of tumor cells was also
observed in the lung and liver (Fig. 3A). To determine the
origin of the tumor cells, immunohistochemistry using
monoclonal antibodies against Thy 1 and CD45 (Phar-
Mingen) was performed on frozen sections of tissues.
As shown in Fig. 3B, these cells were positive for the
T cell-specific surface marker Thy 1 but negative for the
B cell-specific marker CD45 (recognized by the B220
antibody), so these lesions were diagnosed as a T cell
lymphoma.
Expression of E6E7 in the various organs of p531/
2E6E7 transgenic mice
Next, the HPV transgene expression was examined in
the p531/2E6E7 transgenic mice by RT-PCR analysis.
Expression of the HPV transgene was detected in the
normal spleen, thymus, liver, and testis of the p531/
2E6E7 transgenic mice as the three expected tran-
scripts (Fig. 4).
p53 protein defect in lymphoma
The state of p53 in the lymphoma of p531/2E6E7
transgenic mice was examined. By Northern blot analy-
ses, we detected the p53 mRNA expression in normal
spleen and in all tumors analyzed (Fig. 5). Furthermore,
the expression of p53 protein was assessed by immu-
noprecipitation-associated Western blot analysis, and
complete absence of the p53 protein was found in all
tumor tissues (Fig. 6A). The p53 disappearance was also
observed in the tissues where no histological abnormal-
ity was found, indicating that the degradation of p53
occurred before the tumor development. However, we
detected p53 protein in one sample of the spleen that
was ;50% occupied by tumor cells (Fig. 6A, p). By se-
quencing of the p53 cDNA in this sample, a point muta-
tion was found in codon 848 (G to C) of the p53 gene,
which causes an amino acid exchange at amino acid
residue 282, of glutamic acid to glutamine (Fig. 6B). The
lack of destruction of this protein might be due to the fact
that the E6 protein of HPV16 cannot bind and induce the
degradation of mutated p53 protein; moreover, this mu-
tated p53 protein might be essentially stabilized (Scheff-
ner et al., 1990). These observations suggest that p53
function was extinguished via degradation of p53 protein
in the hematopoietic tissues, and this might have poten-
tiated T cell lymphomagenesis.
DISCUSSION
To investigate the transforming activity of the HPV E6
and E7 genes in vivo, we previously established trans-
genic mouse lines containing HPV16E6E7, in which male
mice develop Leydig cell tumors with a very high inci-
dence. In the present study, we investigated the expres-
sion of p53 in this tumor. Although the Leydig cell tumor-
igenesis was induced by HPV oncogenes, p53 expres-
sion was conserved in the tumors at almost the same
level as in normal Leydig cells. To assess the relation-
ship of p53 to the tumorigenesis, the p531/2E6E7 trans-
FIG. 2. Lymphomagenesis in the p531/2E6E7 transgenic mice.
Lymphoma-free survival of mice of each genotype used in this study.
Numbers of mice examined were 25 for p531/1E6E7, 18 for p531/2,
and 17 for p531/2E6E7.
FIG. 1. Expression of p53 gene products in the testicular tumor. (A)
Expression of the p53 transcripts. Samples of 2 mg of poly(A)1 RNA
from mouse testes were subjected to electrophoresis, transferred to a
nitrocellulose membrane, and hybridized with radiolabeled probes for
p53, followed by the hybridization with SRF and GAPDH probes for
quantification. Tumor indicates independent testicular tumors; NT, nor-
mal testis of syngeneic mouse; jsd, germ cell-depleted testis of
C57BL/6 jsd/jsd mouse. (B) Expression of the p53 protein. Nuclear
extracts from the tissues were immunoprecipitated with an anti-p53
monoclonal antibody. The precipitated materials were subjected to
SDS–PAGE, transferred to a nitrocellulose membrane, reacted with
another anti-p53 monoclonal antibody, and detected with the ECL
system. Tu indicates the testicular tumor; Sp, normal spleen of the mice
of p531/1 (positive control) and p532/2 (negative control) genotypes.
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FIG. 3. Histological appearance of the lymphoma developed in the p531/2 E6E7 transgenic mice. (A) The tissues were excised and fixed in Bouin’s
solution. Samples embedded in paraffin were sectioned. All samples were stained with hematoxylin–eosin and then observed under a light
microscope. Immature lymphoid cells with large, coarse nuclei show punctuated nucleoli and a narrow cytoplasm occupying the entire thymus and
spleen. Polynucleated giant cells (GC) were also observed in the spleen. Tumor cell invasions were seen in and around the veins (V) of the lung and
liver. T indicates tumor cells; Ly, normal lymphoid cells. Hematoxylin–eosin staining. Magnification, 320. (B) Immunohistochemistry using anti-Thy1.2
and B220 monoclonal antibodies was performed on frozen sections and finally counterstained with hematoxylin. The lymphoma developed in the
p531/2E6E7 transgenic mice was positive for Thy1 and negative for CD45 (B220). Immunostaining of the lymphoma tissue with anti-Thy1 (left) and
B220 (right). Magnification, 350.
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genic mouse was produced, but it had no change of
tumor phenotype. These observations suggest the lack
of involvement of p53 in Leydig cell tumor development.
Novel T cell lymphomagenesis, however, was ob-
served in all of the p531/2E6E7 transgenic mice.
Because the incidence of lymphoma of the heterozy-
gous p53–disrupted mice (p531/2) was very low
(Fig.2), we considered the lymphomagenesis to be
induced by the HPV transgene. In parallel to the ex-
pression of the HPV transgene in the hematopoietic
organs, the absence of p53 protein was also found in
the spleen from the precancerous stage. Moreover,
the onset of tumorigenesis and the tumor phenotypes
was quite similar to those in the lymphomagenesis of
p53-null mice (p532/2), strongly suggesting that the
HPV16E6 stimulated the degradation of p53 protein
and thereby triggered the carcinogenesis of T cells,
which is known to be very sensitive to p53 destruction.
Therefore, this degradation might be functionally
equivalent to a genetic p53 defect (Table 1) (Done-
hower et al., 1992; Tsukada et al., 1993).
Recently, absence of p53 protein was found in trans-
genic mice expressing HPV16E6 in the skin (Song et al.,
1998). Together with our results, HPV16E6 protein might
stimulate p53 degradation in some cell lineages of the
mouse.
FIG. 4. Expression of HPV16E6E7 transgene in various tissues of the
transgenic mice. RT-PCR products using p5 and p3 as the primers were
subjected to agarose gel electrophoresis and stained with ethidium
bromide. Three types of mRNA [E6/E7 (unspliced), E6*I, and E6*II] are
thought to be expressed from the transgene. The control GAPDH
transcripts are also shown. The p53 genotypes of the respective mice
are indicated. Tg indicates transgenic mouse; wt, syngeneic nontrans-
genic mouse; Sp, spleen; Ty, thymus; Te, testis; Li, liver;and M, size
marker (fX174 digested with HaeIII restriction enzyme).
FIG. 5. Expression of p53 mRNA in the spleen of the p531/-E6E7
transgenic mice. Samples of 20 mg of cytoplasmic RNA from mouse
spleen were subjected to electrophoresis, transferred to a nitrocellu-
lose membrane, and hybridized with radiolabeled probes for mouse
p53. 1/1 indicates normal spleen of p531/1E6E7 transgenic mouse;
1/2, spleen of p531/2E6E7 transgenic mouse occupied with lym-
phoma cells.
FIG. 6. p53 protein absence or mutation in the spleen of the p531/
2E6E7 transgenic mouse. (A) Nuclear extracts from the tissues were
immunoprecipitated with an anti-p53 monoclonal antibody. The precip-
itated materials were subjected to SDS–PAGE, transferred to a nitro-
cellulose membrane, reacted with another anti-p53 monoclonal anti-
body, and detected with the ECL system. Each sample from the p531/
2E6E7 transgenic mice (1/2E6E7) contained various amounts of
lymphoma cells. A lymphoma-free sample was also included (leftmost
lane). Spleen samples from p531/2 (1/2) and p532/2 (2/2) mice
were positive and negative controls, respectively. (B) DNA sequence
analysis of the asterisk-marked (p) sample in A. In one spleen sample
that was ;50% occupied by tumor cells, the p53 protein was detected
(asterisk-marked sample in A). In this sample, the p53 transcript was
subjected to RT-PCR at the hot-spot region, and the sequence was
examined. A point mutation in codon 848 (G to C), which causes an
amino acid exchange at amino acid residue 282 from glutamic acid (E)
to glutamine (Q), was found.
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MATERIALS AND METHODS
Experimental animals
Line 181 transgenic mice and p53-disrupted mice
were used in this study (Kondoh et al., 1994; Tsukada et
al., 1993). Male transgenic mice were crossed with fe-
male mice carrying a p53-disrupted allele, and pups with
four genotypes (p531/1, p531/1E6E7, p531/2, p531/
2E6E7) were obtained. E6E7 transgene and p53-dis-
rupted allele were detected by PCR of DNA extracted
from the mouse tail. All animals were maintained in a
conventional status with free access to food and water.
Histology
Tissues were excised, weighed, and fixed in Bouin’s
solution. Samples embedded in paraffin were sectioned
and stained with hematoxylin–eosin and then observed
under a light microscope.
Immunohistochemistry
The samples were air-dried and then fixed in cold
buffered Formalin–acetone–PBS (25:45:30) for 30 s.
Slides were rinsed three times in 50 mM Tris–HCl, pH
7.6, for 5 min and then washed in 1% H2O2 for 10 min and
incubated with 10% normal rat serum for 10 min at room
temperature. Biotinylated monoclonal antibodies against
mouse Thy-1.2 and CD45 (B220) were applied at 1 mg/ml
overnight at 4°C. Slides were then washed and incu-
bated with a 1:20 dilution of Extravidin Peroxidase
(Sigma) for 30 min. The reaction was developed in dia-
minobenzidine (0.6 mg/ml) containing 0.03% hydrogen
peroxide for 7 min and finally counterstained with hema-
toxylin.
Northern blots
RNA from mouse tissues were prepared according to
the method of Glisin et al. (1974). A sample of 20 mg of
total RNA was denatured and subjected to Formalin–
agarose gel electrophoresis. After transfer of the mate-
rial to a nitrocellulose membrane, hybridization was car-
ried out according to the procedure of Southern (1975).
Mouse p53 and human glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) DNA probes were 32P-radiola-
beled with a multiprime labeling kit (Amersham) before
use for hybridization. The membrane was washed in
stringent conditions and then examined using a Fujix
Bioimage Analyzer (Fuji Film, Japan).
Immunoprecipitation and Western blots
Tissues were homogenized in 0.25 M sucrose–TKM
solution (50 mM Tris–HCl, pH 7.5, 25 mM KCl, 5 mM
MgCl2) at an ice-cold temperature. The homogenate was
overlaid on 2.3 M sucrose–TKM solution and centrifuged
for 30 min at 140,000 g. The nuclear fraction was col-
lected, dissolved in immunoprecipitation buffer (50 mM
HEPES, 500 mM NaCl, 1% Nonidet P-40, and 10 mg/ml
aprotinin) and sonicated. Then, 500 ml of the sonicated
nuclear fraction containing 1 mg of protein was immu-
noprecipitated by incubation with 5 ml of monoclonal
antibody against p53 (AB-1; Oncogene Science) at 4°C
overnight and with 30 ml of Protein A–Sepharose 4B
(Pharmacia) at 4°C for 1 h. The precipitate was collected
by centrifugation and dissolved in 33 sample buffer (6%
SDS, 45 mM Tris–HCl, pH 6.8, 15% 2-mercaptoethanol,
15% glycerol, 0.015% BPB). After removal of Sepharose
through centrifugation, the supernatant was subjected to
10% SDS–PAGE and electrophoretically transferred to a
nitrocellulose membrane. The membrane was probed
with monoclonal antibody against p53 (AB-3; Oncogene
Science), and staining was detected with ECL system
conjugated anti-mouse IgG (Amersham Life Science).
RT-PCR and sequencing
RT-PCR was carried out on the p53 and HPV16E6E7
mRNAs. To avoid false-positive signals generated by
genomic DNA contamination, RNA preparations were
treated with RNase-free DNase I before RT-PCR. Primer
sets for p53 cDNA amplification were p5, 59-CAACTATG-
GCTTCCA CCT-39 (nucleotides 306–324); and p3, 59-AAT-
TTTCTTCTGTA-39 (nucleotides 840–857). The HPV16E6E7
transcription primers were p5, 59-AATGTTTCAG GACC-
CACAGGAGCGACC-39; and p3, 59-GGTCTTCCAAAGTA-
CGAA TGTCTACG-39. The primers for GAPDH amplifica-
tion, as an internal control, were p5, 59-GTCATCAACGG-
GAAG CCCATCACCA-39; and p3, 59-TCTCGTGGTTCAC-
ACCCATCACAAA-39. Amplified p53 cDNA fragments were
sequenced according to the protocol for SequiTherm
Long-Read Cycle Sequencing Kits LC using a LI-COR
sequencer.
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